Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 9/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940596 | 0.93 | ALDH1A1 (0.44) | MKNK1LIMK1EGFRRXFP1KDM4E | |
| SCHEMBL940524 | 0.91 | ALDH1A1 (0.44) | MKNK1LIMK1EGFRRXFP1KDM4E | |
| SCHEMBL937346 | 0.90 | ALDH1A1 (0.41) | MKNK1LIMK1EGFRRXFP1KDM4E | |
| SCHEMBL17296473 | 0.90 | MKNK1 (0.48) | MKNK1LIMK1EGFRRXFP1KDM4E | |
| SCHEMBL17307739 | 0.86 | P2RX3 (0.47) | MKNK1LIMK1EGFRRXFP1KDM4E | |
| SCHEMBL17307632 | 0.85 | EGFR (0.48) | MKNK1EGFRRXFP1KDM4EHSP90AA1 | |
| SCHEMBL17307692 | 0.85 | P2RX3 (0.48) | MKNK1LIMK1EGFRRXFP1KDM4E | |
| SCHEMBL17296440 | 0.85 | P2RX3 (0.49) | MKNK1LIMK1EGFRRXFP1KDM4E | |
| SCHEMBL967213 | 0.83 | RXFP1 (0.66) | MKNK1EGFRRXFP1KDM4E | |
| SCHEMBL17307638 | 0.83 | HSP90AA1 (0.51) | MKNK1LIMK1EGFRRXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | claimed |
| EP-3149004-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181063-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-03 | — | — | WO | claimed |
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2212332-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2212332-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | TYMP, DPYD, TYMS | MKNK1 2433/4885LIMK1 3945/4885EGFR 1017/4885 |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, CYP11B1, CYP11A1 | MKNK1 3496/4885LIMK1 4207/4885EGFR 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.